ABIOMED, Inc. (ABMD) Hit 52-Week High at $332.45 on May, 3

May 3, 2018 - By Sarah Harris

ABIOMED, Inc. (NASDAQ:ABMD) Corporate Logo

During Q4 2017 the big money sentiment decreased to 1.18. That’s change of 0.12, from 2017Q3’s 1.3. 19 investors sold all, 110 reduced holdings as ABIOMED, Inc. ratio dived. 97 rose holdings while 55 funds amassed holdings. Funds hold 36.44 million shares thus 5.39% less from 2017Q3’s 38.51 million shares.
Cibc Asset holds 1,468 shs or 0% of its capital. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in ABIOMED, Inc. (NASDAQ:ABMD). Commercial Bank Of America Corporation De owns 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 25,834 shs. Stifel owns 2,946 shs. Pnc Financial Grp Inc owns 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 9,814 shs. Retirement Systems Of Alabama holds 77,415 shs. Primecap Management Ca reported 0.59% in ABIOMED, Inc. (NASDAQ:ABMD). Spectrum Mngmt Group Inc reported 8 shs stake. Aqr Mgmt Limited Liability, Connecticut-based fund reported 124,135 shs. Enterprise Financial Ser owns 0% invested in ABIOMED, Inc. (NASDAQ:ABMD) for 10 shs. Blair William & Il accumulated 0.48% or 379,886 shs. Nicholas Prtnrs L P has invested 0.85% of its capital in ABIOMED, Inc. (NASDAQ:ABMD). Commonwealth Of Pennsylvania School Empls Retrmt Sys invested in 6,135 shs or 0.02% of the stock. Fmr Ltd Company invested in 0.01% or 267,866 shs. Tiaa Cref Mngmt Ltd Llc, a New York-based fund reported 165,688 shs.

ABIOMED, Inc. had 1 sale and 0 insider purchases since February 20, 2018. This’s net activity of $5.41 million.

ABIOMED, Inc. (NASDAQ:ABMD) touched 52 week high touching $332.45. Our PT is $345.75. On May, 3 the 52 week high was reported by Barchart.com. The company has $14.72 billion market cap. $588.80 million more could be NASDAQ:ABMD valuation at $345.75 share price.

ABMD hit $332.45 during the last trading session after $30.31 change.Currently ABIOMED, Inc. is uptrending after 128.67% change in last May 3, 2017. ABMD has 358,671 shares volume. ABMD outperformed the S&P 500 by 117.12%.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

In total 8 analysts cover Abiomed (NASDAQ:ABMD). “Buy” rating has 7, “Sell” are 0, while 1 are “Hold”. (NASDAQ:ABMD) has 88% bullish analysts. With $370.0 highest and $220.0 lowest PT, Abiomed has $312.75 average PT or -5.93% below the current ($332.45) price. 12 are the (NASDAQ:ABMD)’s ratings reports on May 3, 2018 according to StockzIntelligence Inc. On Thursday, December 21 the rating was maintained by Jefferies with “Buy”. In Tuesday, May 1 report Morgan Stanley maintained the stock with “Equal-Weight” rating. On Thursday, January 4 the firm earned “Buy” rating by Piper Jaffray. On Friday, February 16 the rating was maintained by SunTrust with “Buy”. On Monday, April 9 Stephens maintained ABIOMED, Inc. (NASDAQ:ABMD) rating. Stephens has “Buy” rating and $30000 target. On Friday, February 2 the company was maintained by Stephens. On Thursday, February 1 the stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Piper Jaffray. In Friday, February 2 report Guggenheim maintained it with “Buy” rating and $280.0 target. On Friday, February 2 the stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Equal-Weight” rating given by Morgan Stanley. On Thursday, February 1 the firm earned “Buy” rating by Jefferies.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.The firm is valued at $14.72 billion. It also provides continuum of care to heart failure patients.The P/E ratio is 166.81. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: